| Value | ₹120.0 Cr |
|---|
BSE filing, NSE: NETWEB. Summary written from the filing by ALFA Finder's alert engine.
Netweb Technologies India Ltd: key numbers
- Share price
- ₹4,172.60
- Market cap
- ₹24,805 Cr
- Revenue (annual)
- ₹2,184 Cr
- Net profit (annual)
- ₹205.8 Cr
- P/E (TTM)
- 67.8×Sector 23.5×
- Promoter holding
- 64.16%-2.82% QoQ
- FII holding
- 9.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Netweb Technologies India Ltd
All →Netweb Technologies India Other Announcement
Netweb's monitoring agency reported QIP proceeds were used as disclosed, with no deviation from objects. The report covers the quarter ended September 30, 2026.
Netweb Technologies India Earnings Call Transcript: Key Takeaways
Netweb delivered explosive 335% revenue growth driven by India's AI infrastructure surge. While H1 PAT has already surpassed the entire FY26, gross margins are under pressure from raw material costs and large deal mix.
- Call
- Guides 40% growth
Netweb Technologies India Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹13,233 Mn (+335.7% YoY), operating EBITDA ₹1,973 Mn (14.9%), PAT ₹1,367 Mn (10.2%). AI Systems is 58.4% of revenue. ₹12,000 Mn raised via QIP.
Netweb Technologies India Results Update
Netweb's Q2 FY27 revenue rose 335.7% YoY to ₹13,233 Mn, with PAT of ₹1,367 Mn. H1 FY27 PAT of ₹2,220 Mn already exceeds full-year FY26 PAT.
Netweb Technologies India Q2 FY27 Results: Net Profit ₹136.7 Cr, Up 335.4% YoY
Netweb Technologies India Ltd reported revenue from operations of ₹1,323 Cr (+335.7% YoY) and net profit of ₹136.7 Cr (+335.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹136.7 Cr · +335.4% YoY
Netweb Technologies India Board Meeting Date
Netweb Technologies India Limited scheduled a board meeting on October 24, 2026, to consider and approve the company's unaudited financial results for the quarter ended September 2026.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr